Live Breaking News & Updates on Bimagrumab

Stay updated with breaking news from Bimagrumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Eli Lilly to buy weight loss drugmaker for $1.93B

Eli Lilly agreed to acquire Versanis for $1.93 billion to boost its weight loss drug treatment portfolio. ....

Novo-nordisk-wegovy , Eli-lilly , Novo-nordisk , Ersanis , Besity , Bimagrumab , Onoclonal-antibody , Glp-1-agonists , Egovy , Zempic , Harma , Ortfolio

Treatment with Bimagrumab safe for patients with obesity, diabetes


Treatment with Bimagrumab safe for patients with obesity, diabetes
Bimagrumab is an antibody that blocks activ in type II receptors and stimulates skeletal muscle growth
Thursday January 14, 2021 12:14 PM, IANS
New York: Researchers have found that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and Type-2 diabetes.
Bimagrumab is an antibody that blocks activ in type II receptors and stimulates skeletal muscle growth.
These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits, said researcher Steve Heymsfield from Pennington Biomedical Research Center, in the US. ....

New-york , United-states , Steve-heymsfield , Pennington-biomedical-research-center , Weight-loss-new , Bimagrumab , Treatment-with-bimagrumab , Obesity , Weight-loss-new-treatment , Type-2-diabetes , Eactiv , Body-fat-loss

Welcome To IANS Live - ENTERTAINMENT - Novel way for weight loss in patients with obesity, diabetes


Photo Credit: IANS
IANSLive
New York, Jan 14 (IANS) Researchers have found that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and Type-2 diabetes.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 14-January-2021 ....

New-york , United-states , India , Twitter , India-private , News-service , All-rights , Bimagrumab , Placebo , Weight , Per-cent